TCT 2023: Six-Month Clinical Data from DESyne® BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy
Elixir Medical announced positive six-month clinical data from the DESyne BDS Plus Randomized Controlled Trial (RCT) evaluating DESyne BDS Plus versus a second-generation, durable polymer drug-eluting stent (DES).
Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus At TCT 2023
Elixir Medical will present primary endpoint and 6-month data from its DESyne BDS Plus Randomized Clinical Trial (RCT), a prospective, multicenter, single-blind study, as part of The Innovation Program at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments That Uncage the Stented Artery
Elixir Reveals New Category of ‘Bioadaptive Drug Eluting Stents’ (BA- DES), Sharing DynamX Technology, Preclinical Data, and Clinical Program at 29th Transcatheter Cardiovascular Therapeutics Conference Milpitas, Calif. (October 31, 2017) – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling technologies designed to mimic the normal arterial function after cardiovascular and peripheral […]
Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results for Thin-Strut DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that a successful live case demonstration of its next-generation DESolve® NXT Plus Novolimus Eluting Bioresorbable Coronary Scaffold System was presented at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC. “This live demonstration presented […]
Successful Live Case Demonstration of Elixir Medical’s Fully Bioresorbable DESolve NXT Plus Novolimus Eluting Coronary Scaffold System at TCT
Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that a successful live case demonstration of its next-generation DESolve® NXT Plus Novolimus Eluting Bioresorbable Coronary Scaffold System was presented at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC. “This live demonstration presented […]
Elixir Medical Announces Successful Live Case Transmission of DESolve Cx at TCT
Sunnyvale, Calif. – October 13, 2015 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that on Mon., October 12, Professor Alexandre Abizaid, M.D., Ph.D., of The Instituto Dante Pazzanese de Cardiologia, Brazil, conducted a successful implantation of its breakthrough and fully bioresorbable DESolve® Cx Novolimus Eluting Coronary Scaffold System that […]